The Batch That Should Not Exist: How a Falsified Cancer Drug in Kenyan Pharmacies Is Stalking the Diaspora's Hospital Bills

She read the WhatsApp message twice before she trusted it. It was just after 7 a.m. in Silver Spring, Maryland, and the sender was her younger sister in Nairobi. Their mother's oncologist had switched her from the long intravenous infusion to a quick injection under the skin. The new drug, the sister wrote, was called Phesgo. It was working. The bill was due on Sunday and the dose alone was the better part of two thousand dollars.

The caregiver in Maryland did what thousands of Kenyans in the diaspora have learned to do in a cancer year. She forwarded the figure to her cousin in Manchester, asked her sister-in-law in Sydney to chip in, and opened her M-Pesa app while she made coffee. Phesgo, she told herself, was the breakthrough drug for HER2-positive breast cancer. Her mother was finally tolerating the chemo, and the new injection was supposed to make the next six months easier.

What she did not yet know was that, on the same morning, in Nairobi, a different document was making the rounds. Kenya's Pharmacy and Poisons Board had issued a public alert. A falsified batch of Phesgo, labelled C5290S20, was already circulating in the local market. Inside the vials, regulators said, was a white powder. The genuine drug is supposed to arrive as a clear-to-opalescent liquid that needs no reconstitution. Whatever was in those vials, the alert warned, was not Roche's medicine.

What the regulator actually found

The board, known by its acronym PPB, said the falsified batch was detected during routine post-marketing surveillance. The C5290S20 label, attached to the 600mg/600mg vial in the 10ml presentation, corresponds to no batch ever produced by Roche. The contents inside the vial, that powder rather than a ready-to-use solution, were the strongest tell that the drug had been tampered with or invented from scratch.

In its public notice, the board did not estimate how many vials had reached pharmacies, hospitals or private oncology clinics. It did ask procurement agencies, distributors, wholesalers, retailers, pharmacists, pharmaceutical technologists and the wider public to stop dispensing the batch immediately and to report any vials they had already received. The PPB also reminded the trade that procuring medicines outside licensed channels is an offence under the Pharmacy and Poisons Act, and signalled enforcement action against anyone still moving the batch.

What the regulator could not tell patients was whether the drug they had already been injected with this month was authentic. That is a question only the manufacturer's tracing data and the hospital pharmacies' procurement records can answer. For now, the burden has fallen on patients, families and the diaspora that funds many of them.

Why the diaspora carries the bill

Phesgo is a high-value biologic. The drug combines pertuzumab and trastuzumab in a single injection, with hyaluronidase added so it absorbs under the skin in a matter of minutes instead of an intravenous infusion that can stretch over hours. For HER2-positive breast cancer, an aggressive subtype that responds well to targeted therapy, Phesgo is one of the standard tools of modern oncology. A single dose, depending on the supplier, costs in the low thousands of dollars.

In Kenya, where the public insurance scheme has only partial cover for oncology biologics, that price quickly becomes a family conversation rather than a clinical one. The conversation runs across borders. M-Changa fundraisers for cancer treatment routinely cite Phesgo, Herceptin and Perjeta in their itemised budgets. M-Pesa notifications arrive from Atlanta, Boston, Doha, Dubai, Birmingham and Brisbane. WhatsApp groups built around a single patient sometimes have more contributors abroad than at home.

The diaspora is not merely sentimental about this. It is, in many oncology wards, the actual payer. When a counterfeit batch enters that supply chain, the financial loss is borne overwhelmingly by people who never stepped inside the hospital pharmacy that dispensed the vial.

A batch with a passport

The C5290S20 label has a history in Africa that predates this week. Earlier this year, Nigeria's National Agency for Food and Drug Administration and Control, NAFDAC, issued its own alert against an identically labelled falsified Phesgo batch circulating in the Nigerian market. The vials there also contained a white powder. The fingerprint is the same. The regulator's language is the same. The patients put at risk are the same kind of patients, predominantly women, predominantly in mid-treatment, predominantly relying on family abroad to pay.

That a single counterfeit batch can move between national markets, and reappear with the same fake number on the same drug at the same dose, points to an organised supply chain rather than an opportunistic local scam. Regulators across the continent have for years warned that falsified oncology medicines, especially biologics whose prices make small batches lucrative, are an emerging public-health crisis. The Phesgo trail through Lagos and Nairobi gives that warning a serial number.

What the diaspora caregiver can do now

For families with relatives currently on Phesgo, the PPB's advice is narrow but useful. Ask the treating oncologist or hospital pharmacist for the batch number on the vial. If the label reads C5290S20 in the 600mg/600mg 10ml presentation, do not allow another dose to be administered. Report the vial to the PPB. Where possible, request that all oncology biologics be procured through the hospital pharmacy of a manufacturer-licensed distributor, with the import paperwork made visible to the family.

For families about to start treatment, the advice runs further. Ask, before the first injection, whether the dose has been verified against a manufacturer-issued batch. Keep photographs of every vial label. Send those photographs to the diaspora-side caregiver who is paying. That person now has a regulatory role to play, not just a financial one.

It is an awkward request to make of an oncology ward. But the PPB has, in effect, asked patients and families to become the last line of inspection. The diaspora, which already operates as the last line of finance, can do this part by extending the same forensic discipline it brings to remittance receipts.

The wider shadow over Kenyan oncology

The Phesgo alert is not the first of its kind in Kenya, and it will not be the last. Earlier this year, the PPB warned of a falsified version of IBRANCE, a different breast cancer drug. In 2024, the board issued a parallel alert over fake cancer pills with no active ingredient. The pattern is consistent. High-priced oncology medicines, sold across a fragmented distribution network, are an attractive target for counterfeiters with international reach.

For the Kenyan diaspora, the consequence is not abstract. The cancer fund opened in a Maryland kitchen, the M-Pesa transfer sent from Doha at 3 a.m., the Sydney rent stretched thin so a Nairobi mother can have one more cycle of Phesgo, these are commitments built on the assumption that the medicine is real. The PPB alert this week is a reminder that the assumption needs to be checked, vial by vial, batch by batch, until the supply chain catches up to the diaspora's trust in it.